Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 20;8(50):87442-87454.
doi: 10.18632/oncotarget.21103. eCollection 2017 Oct 20.

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

Puyuan Xing  1 , Yixiang Zhu  1 , Ling Shan  2 , Sipeng Chen  3 , Xuezhi Hao  1 , Junling Li  1
Affiliations

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

Puyuan Xing et al. Oncotarget. .

Abstract

For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m2) on days 1, 8 of a 21-day cycle were included. The median progression-free survival (PFS) and overall survival (OS) were 4.34 months (95% confidence interval [CI] 3.508 to 5.165 months) and 11.73 months (95% CI 9.211 to 14.247 months), respectively. The objective responses rate (ORR) and disease control rate (DCR) were 22.4% and 74.5%. Prior treatment with taxane and line of therapy did not influence the efficacy of Nab-PTX. The main grade 3 to 4 toxicities were neutropenia (25.5%) and leukopenia (12.4%). Furthermore, 24 cases offered samples to assess secreted protein acidic and rich in cysteine (SPARC) expression. No statistical difference was observed in treatment efficacy between SPARC expression-negative and positive. The findings suggest that weekly Nab-PTX monotherapy is effective and well tolerated for patients with pretreated advanced NSCLC, regardless of prior taxane exposure or line of therapy.

Keywords: advanced non-small cell lung cancer (NSCLC); multiple treatments; nanoparticle albumin bound paclitaxel (Nab-PTX); secreted protein acidic and rich in cysteine (SPARC); taxane.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) for the entire populations and patients with or without prior taxane treatment
(A) The PFS curves for all patients. (B) The OS curves for all patients. (C) The PFS curves stratified by prior taxane exposure. (D) The OS curves stratified by prior taxane exposure. N, number; CI, confidence interval; p, p value.
Figure 2
Figure 2. Immunohistochemical expression using monoclonal antibody (R&D system, MAB941) of secreted protein acidic and rich in cysteine (SPARC)
(A) Tumors with score of 0; (B) Tumors with score of 1+; (C) Tumors with score of 2+; (D) Tumors with score of 3+. Tumors with a score of 0 or 1+ were regarded as negative for SPARC expression, and those with a score of 2+ or 3+ were regarded as positive for SPARC expression.
Figure 3
Figure 3. The Progression-free survival (PFS) and overall survival (OS) curves stratified by secreted protein acidic and rich in cysteine (SPARC) expression
(A) The PFS curves stratified by SPARC expression. (B) The OS curves stratified by SPARC expression. Negative, tumors with negative SPARC expression; Positive, tumors with positive SPARC expression; N, number; CI, confidence interval; p, p value.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44. - PubMed
    1. Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M. The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. Ther Adv Med Oncol. 2010;2:301–7. - PMC - PubMed
    1. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–12. - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–35. - PMC - PubMed
    1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50. - PubMed

LinkOut - more resources